Shilpa Biologicals partners with mAbTree Biologics AG for a novel immunooncology asset
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m
Experts urge early detection & better access to care
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
The European regulator will conduct a re-inspection of the facility to verify the compliance
Announces Rs. 317 crore investment in new recycling plant
Overall investment in the US facility is estimated around US$50 million
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
Subscribe To Our Newsletter & Stay Updated